Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/cmdc.202500554 http://scihub22266oqcxt.onion/10.1002/cmdc.202500554 41319337!?!41319337       ChemMedChem 2025 ; ? (?): e202500554 Nephropedia Template TP {{tp|p=41319337|t=2025. Nature-Inspired Myelocytomatosis Oncogene Inhibitor Disrupts Myelocytomatosis Oncogene-Driven Glycolysis and Restricts Ovarian Tumor Growth |pdf=|usr=}}{{41319337}} gab.com Text Nature-Inspired Myelocytomatosis Oncogene Inhibitor Disrupts Myelocytomatosis Oncogene-Driven Glycolysis and Restricts Ovarian Tumor Growth JO: ChemMedChem http://www.kidney.de/pget.php?&tw=1&pmid=41319337 #FOAvip Myelocytomatosis oncogene (MYC) inhibitors are not available for clinical applications because the MYC protein is not part of a receptor-ligand pair and lacks a defined binding site for small molecules. GD-07, drug-like small molecule identified throughcheminformatics that selectively binds to the G-quadruplex (G4) in the c-MYC promoter with high binding affinity and selectivity over dsDNA. NMR analysis reveals that GD-07 binds to the upper tetrad of c-MYC G4. It exhibits a favorable pharmacokinetic profile and high cytotoxicity in ovarian cancer (OC) cells (A2780) compared to the standard drug carboplatin. Normal cells show no sensitivity to GD-07, indicating a broad therapeutic window. GD-07 suppresses MYC expression, curbing glucose metabolism, and glycolysis while promoting p53 and proapoptotic markers in OC cells. In patient-derived OC organoids, GD-07 shows greater activity than carboplatin with promising clinical translatability. Twit Text FOAVip Nature-Inspired Myelocytomatosis Oncogene Inhibitor Disrupts Myelocytomatosis Oncogene-Driven Glycolysis and Restricts Ovarian Tumor Growth ????ChemMedChem http://www.kidney.de/pget.php?&tw=1&pmid=41319337 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41319337 #FOAvip English Wikipedia <ref>{{Cite pmid|41319337}}</ref> Nature-Inspired Myelocytomatosis Oncogene Inhibitor Disrupts Myelocytomatosis Oncogene-Driven Glycolysis and Restricts Ovarian Tumor Growth #MMPMID41319337 Singh M; Yadav A; Singh U; Gupta R; Cavarzerani E; Canzonieri V; Negi D; Dagar A; Sathyamoorthy B; Rizzolio F; Kumar S; Baliyan A; Rani R; Kumar V ChemMedChem 2025[Nov]; ? (?): e202500554 PMID41319337show ga Myelocytomatosis oncogene (MYC) inhibitors are not available for clinical applications because the MYC protein is not part of a receptor-ligand pair and lacks a defined binding site for small molecules. GD-07, drug-like small molecule identified throughcheminformatics that selectively binds to the G-quadruplex (G4) in the c-MYC promoter with high binding affinity and selectivity over dsDNA. NMR analysis reveals that GD-07 binds to the upper tetrad of c-MYC G4. It exhibits a favorable pharmacokinetic profile and high cytotoxicity in ovarian cancer (OC) cells (A2780) compared to the standard drug carboplatin. Normal cells show no sensitivity to GD-07, indicating a broad therapeutic window. GD-07 suppresses MYC expression, curbing glucose metabolism, and glycolysis while promoting p53 and proapoptotic markers in OC cells. In patient-derived OC organoids, GD-07 shows greater activity than carboplatin with promising clinical translatability. ?Nature-Inspired Myelocytomatosis Oncogene Inhibitor Disrupts Myelocyto(epmc).pdf DeepDyve Pubget Overpricing